107 related articles for article (PubMed ID: 9667586)
1. To tap or not to tap: cerebrospinal fluid biomarkers of Alzheimer's disease.
Growdon JH
Ann Neurol; 1998 Jul; 44(1):6-7. PubMed ID: 9667586
[No Abstract] [Full Text] [Related]
2. Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1-40, (Abeta40), beta-amyloid 1-42 (Abeta42) and total Tau.
Stuerenburg HJ; Ganzer S; Müller-Thomsen T
Neuro Endocrinol Lett; 2005 Dec; 26(6):696-8. PubMed ID: 16380679
[TBL] [Abstract][Full Text] [Related]
3. Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease.
Skogseth R; Mulugeta E; Jones E; Ballard C; Rongve A; Nore S; Alves G; Aarsland D
Dement Geriatr Cogn Disord; 2008; 25(6):559-63. PubMed ID: 18536520
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid biomarkers in Alzheimer's disease: are the hypotheses more dynamic than the biomarkers?
Spies PE; Verbeek MM; Olde Rikkert MG; Claassen JA
J Am Geriatr Soc; 2010 Aug; 58(8):1619-20. PubMed ID: 20942893
[No Abstract] [Full Text] [Related]
5. New tests for Alzheimer's disease.
Health News; 2006 Jun; 12(6):2. PubMed ID: 16826618
[No Abstract] [Full Text] [Related]
6. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
[TBL] [Abstract][Full Text] [Related]
7. [Biochemical markers for Alzheimer disease].
Czarna JM; Waldemar G; Heegaard NH
Ugeskr Laeger; 2006 Mar; 168(10):1010-4. PubMed ID: 16522291
[TBL] [Abstract][Full Text] [Related]
8. [The progress of Alzheimer's disease research biomarkers--sensitivity and specificity].
Shoji M
Rinsho Shinkeigaku; 2000 Dec; 40(12):1234-6. PubMed ID: 11464465
[TBL] [Abstract][Full Text] [Related]
9. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.
Andreasen N; Blennow K
Clin Neurol Neurosurg; 2005 Apr; 107(3):165-73. PubMed ID: 15823670
[TBL] [Abstract][Full Text] [Related]
10. [Alzheimer's disease as brain amyloidosis: diagnosis using cerebrospinal fluid abeta and tau].
Shoji M
Rinsho Byori; 2006 May; 54(5):503-8. PubMed ID: 16789421
[TBL] [Abstract][Full Text] [Related]
11. Usability of cerebrospinal fluid biomarkers in a tertiary memory clinic.
Brandt C; Bahl JC; Heegaard NH; Waldemar G; Johannsen P
Dement Geriatr Cogn Disord; 2008; 25(6):553-8. PubMed ID: 18536519
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.
Galasko D
J Neural Transm Suppl; 1998; 53():209-21. PubMed ID: 9700659
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
[TBL] [Abstract][Full Text] [Related]
14. [Biomarkers in cerebrospinal fluid and blood in memory complaints].
Zetterberg H; Andreasen N; Blennow K
Lakartidningen; 2009 May 13-19; 106(20):1386-9. PubMed ID: 19585836
[No Abstract] [Full Text] [Related]
15. [Neurochemical early and differential diagnostics for Alzheimer's disease].
Wiltfang J; Lewczuk P; Maler M; Bleich S; Smirnov A; Kornhuber J
MMW Fortschr Med; 2004 Sep; 146(38):38-40. PubMed ID: 15532429
[TBL] [Abstract][Full Text] [Related]
16. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
Parnetti L; Lanari A; Silvestrelli G; Saggese E; Reboldi P
Mech Ageing Dev; 2006 Feb; 127(2):129-32. PubMed ID: 16274728
[TBL] [Abstract][Full Text] [Related]
17. Biological markers in cerebrospinal fluid (CSF) and evaluation of in vitro effect of CSF on PC12 cell line viability in Alzheimer's disease.
Yaka E; Egrilmez MY; Keskinoglu P; Cavdar Z; Genc S; Genc K; Iyilikci L; Yener GG
Cell Biochem Funct; 2009 Aug; 27(6):395-401. PubMed ID: 19639578
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.
Kanai M; Matsubara E; Isoe K; Urakami K; Nakashima K; Arai H; Sasaki H; Abe K; Iwatsubo T; Kosaka T; Watanabe M; Tomidokoro Y; Shizuka M; Mizushima K; Nakamura T; Igeta Y; Ikeda Y; Amari M; Kawarabayashi T; Ishiguro K; Harigaya Y; Wakabayashi K; Okamoto K; Hirai S; Shoji M
Ann Neurol; 1998 Jul; 44(1):17-26. PubMed ID: 9667589
[TBL] [Abstract][Full Text] [Related]
19. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
Formichi P; Battisti C; Radi E; Federico A
J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
